Clinical Trial Update: RANOLAZINE STUDY: Speckle Tracking Derived Myocardial Strain

View source ↗

Summary

The Ranolazine study evaluating speckle-tracking derived myocardial strain has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Ischemic Cardiomyopathy

Drugs mentioned

• Ranolazine (ranolazine)

Snippet

Sponsor: Saint Thomas Health | Conditions: Severe Coronary Artery Disease, Ischaemic Myocardial Dysfunction | Status: WITHDRAWN